Dolin v. GlaxoSmithKline LLC’s Empirical Analysis
901 F.3d 803 · 2018
Citation profile
1 federal appellate · 1 district · 1 state decisions
Relationships
Applies 21 U.S.C. § 331 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act) · 28 U.S.C. § 1332 (Class Action Fairness Act of 2005)
Relies on Erie Co v. Tompkins · Gibbons v. Ogden · Hillsborough County v. Automated Medical Laboratories, Inc. · Boyle v. United Technologies Corp. · Wyeth v. Levine
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 5 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“given the facts [of the] case, no reasonable jury could find that the FDA would have approved [plaintiffs' proposed warning] under the CBE regulation”
1 later decision quote this exact passage · from the majority“'clear evidence that the FDA would not have approved a change' to the [prescription drug's] label.”
1 later decision quote this exact passage · from the majority“a labeling deficiency that [Defendants] could have corrected using the CBE regulation.”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.